Anticancer Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025

Published on : Nov-2019 | List of Tables : 40 | List of Figures : 79 | No. of Pages : 170 | Report Code : FACT4350MR | Format : ppt pdf Excel Word

Awareness Campaigns Launched by Central Authorities to Underpin Anticancer Drugs Market Growth

The sales of anticancer drugs are gaining strength, as a large number of awareness campaigns are being initiated by governments and central authorities, at a global level. The National Breast Cancer Foundation, Inc. runs an annual campaign by observing October as breast cancer awareness month, to spread information regarding the disease and encourage women to undergo screening tests. Such initiatives are increasing the number of diagnoses, inadvertently creating a large patient pool for anticancer drugs. Increase in funding to support the research & development of anticancer therapeutics is leading to advancements in treatment approaches and routes of administration. Development of therapeutics with better patient outcomes and lesser side-effects than conventional ones is projected to increase patients’ trust in these drugs, thereby strengthening the growth prospects of the anticancer drugs market.

Besides this, the U.S. Food and Drug Administration (FDA) designates the status of 'orphan drugs' to medications that hold promising potential for the treatment of rare diseases. To further support the development of highly-effective drugs for rare diseases such as cancer, the FDA offers incentives such as market exclusivity and tax credits for clinical trials. On the backdrop of these dynamics, the demand and supply of these drugs is projected to rise, thereby boosting the growth of the global anticancer drugs market. As such, the sales of these drugs are projected to reach ~US$ 156 Bn by 2025.

key segments in anticancer drugs market

For detailed insights on market taxonomy, request a sample copy of the report here.

Targeted Therapies to Gain Momentum as Treatment with Lesser Side-effects

Despite a rapid rise in cancer diagnostic rates, the sales of anticancer drugs are yet to realise their true potential. Increasing awareness regarding the side-effects of anticancer therapies such as hair loss, anaemia, constipation, infection and neutropenia, sexual health issues, and bleeding and bruising are projected to increase consumer inclination towards natural therapeutics. In regions such as Southeast Asia, the Middle East and Africa, India, and China, patients are adopting alternative therapeutics such as Ayurveda medicines, homeopathic medicines, and herbal medicines, which could negatively impact the sales of anticancer drugs market during the forecast period (2020 - 2025).

To offset this impact, market players are entering into co-development partnerships aimed at leveraging mutual strengths to introduce advanced anticancer drugs, while significantly reducing time to market. Targeted drugs are one such advancement, which take specific action against cancer cells and have no negative impact on the other cells. In 2020, targeted drugs are projected to account for ~44% of the total sales recorded in the anticancer drugs market, which is indicative of shifting patients’ preference towards targeted therapeutics.

Market Players Experimenting with Combination of Drugs to Enhance Efficiency

In order to lower cancer mortality rates, companies are designing models of combination therapies, wherein, two or more therapeutic agents are combined to further increase the efficacy of drugs. For instance, The U.S. Food and Drug Administration (FDA) approved a combination of Abraxane and gemcitabine to be used as the first-line of treatment of metastatic pancreatic cancer. This combined drug therapy is specifically approved for adenocarcinoma of the pancreas, which accounts for around 95% of cancers of the pancreas. Growing information regarding the high efficiency of combined drug therapy is projected to drive profitability of the anticancer drugs market during the forecast period.

Besides this, advancements in targeted therapy - oral targeted therapy - offer convenience of treatment to patients. With the help of oral targeted therapies, small-molecule inhibitors are administered orally in an oncology setting, targeting and destroying cancer cells. Such initiatives undertaken by players in the anticancer drugs market are projected to pave the way for the advancements of therapeutics, which will further boost the sales of these drugs.

key regions in anticancer drugs market

For detailed regional analysis, request a sample copy of the report here.

Higher Market Share on the Horizon for Asia Pacific Anticancer Drugs Market

North America is projected to contribute a significant share, i.e. ~42% to the global anticancer drugs market by 2025. There has been an increase in the rate of early diagnosis, on the back of high awareness regarding the prevalence of cancer and its types among individuals in the U.S. and Canada. Targeted efforts by the governments in these countries to fuel research & development activities of market players are projected to increase the availability of drugs, and, in turn, strengthen the pipeline in this region.

However, players are increasingly focused on entering into the highly lucrative Asia Pacific market, owing to progressive improvements in healthcare infrastructure and facilities. Besides this, Asia Pacific is also gaining prominence as a medical tourism destination, owing to cost-effective, yet quality healthcare services offered by private and public healthcare facilities. On account of this, the market share of Asia Pacific is projected to grow significantly by 2025.

Request research methodology of this report.

Anticancer Drugs Market - Scope of the Study

Fact.MR, in its exclusive research report on the anticancer drugs market, highlights actionable insights and winning imperatives for stakeholders. This comprehensive study unfolds rare and distinguished intelligence regarding impactful dynamics, which directly or indirectly influence the growth of the anticancer drugs market during the forecast period (2020 - 2025). With the help of crucial insights discussed in this study, stakeholders will gain a thorough idea regarding the growth trajectory of the anticancer drugs market.

This comprehensive study offers incisive data regarding the drivers, threats, restraints, and opportunities present in the anticancer drugs market. The study also recalibrates the impact of each of these dynamics to estimate the size of the anticancer drugs market for the given period. Authors of the report have taken ample care to measure and include the relevance and impact of microeconomic as well as macroeconomic factors that hold potential to influence the growth of the anticancer drugs market during the forecast period.

The global study on the anticancer drugs market includes Porter’s Five Forces analysis, in order to present the buyer’s and supplier’s power in the anticancer drugs landscape. In addition, the analysis also discusses the threat of substitutes and new entrants, which provides a brief idea regarding the future growth course of the anticancer drugs market.

The global study offers crucial information about global, regional, and local players operating in the anticancer drugs market, along with their estimated market share. The market share has been estimated in terms of value (US$ Mn). Besides providing key information regarding the concentration of leading, prominent, and local players, the study also aims at equipping stakeholders with the best of information regarding the winning strategies, recent developments, and financials.

Anticancer Drugs Market - Assessment of Key Segments

With an aim to offer granular level insights into the anticancer drugs market, authors of the report have segmented the landscape on the basis of drug type, therapy, cancer type, and region. This global research report also analyses the incremental opportunity available in the anticancer drugs market during the forecast period. Key segments of the anticancer drugs market include:

Drug Type

Therapy

Cancer Type

Region

Targeted Drugs

Chemotherapy

Lung Cancer

North America

Cytotoxic Drugs

Targeted Therapy

Breast Cancer

Europe

Hormonal Drugs

Immunotherapy

Leukemia

Asia Pacific

 

Others

Colorectal Cancer

Latin America

 

 

Others

Middle East & Africa

This detailed guide, based on the latest market movement, ensures that only precise information reaches stakeholders, so as to help them gain an upper hand over their competitors in the global anticancer drugs market. This exclusive guide offers crucial information about the current trends, pipeline drugs, unmet drugs, future scope, and government regulations for the anticancer drugs market.

A list of leading, prominent, and emerging players operating in the global anticancer drugs market is included in this comprehensive study, which consists of F.Hoffmann-La Roche Ltd, Novartis AG, Eli Lily and Company, Amgen Inc., Pfizer Inc., CELGENE CORPORATION, Bayer AG, Merck & Co., Inc., AstraZeneca, and Takeda Pharmaceutical Company Limited.

Anticancer Drugs Market - Research Methodology

The research undertaken by seasoned analysts at Fact.MR consists of a systematic approach, including both, the primary and secondary research methodology. For conducting primary research, interviews and discussions were carried out with industry experts, key opinion leaders, vendors, and distributors. Besides these, respondents also include CEOs, Presidents, directors, chairmen, vice presidents, marketing managers, suppliers, distributors, and chief medical officers, among others. This helps in assessing the demand-supply gap prevailing in the anticancer drugs market.

In order to conduct secondary research, marketing collaterals, company websites, industry associations, and government statistics were studied. In addition to this, reports as well as content pieces published by credible sources, such as the Stock analyst websites, such as Seeking Alpha, Growth Financial, Yahoo Finance, and others were studied.

Besides this, governmental and public portals, such as World Health Organizations (WHO), FDA websites, Clinicaltrials.gov (U.S.), European Medicines Agency (EMA), Centres for Disease Control and Prevention (CDC), American Cancer Society, and National Health Services (NHS), were referred to, to gain crucial information regarding key players in the anticancer drugs market. Insights obtained through primary and secondary research are then authenticated with the data triangulation method.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anticancer Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity

        4.3.4. Trends

    4.4. Global Anticancer Drugs Market Analysis and Forecasts, 2015-2025

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

    4.6. Value Chain Analysis

    4.7. Market Outlook

    4.8. Pipeline Analysis

    4.9. Disease Overview

    4.10. Evolution of Cancer Therapies

5. Global Anticancer Drugs Market Analysis and Forecasts, By Drug Type 

    5.1. Introduction & Definition

    5.2. Key Findings / Developments

    5.3. Market Value  Forecast By Drug Type , 2015-2025

        5.3.1. Cytotoxic Drugs

            5.3.1.1. Alkylating Agents

            5.3.1.2. Antimetabolites

            5.3.1.3. Others

        5.3.2. Targeted Drugs

            5.3.2.1. Monoclonal Antibodies

            5.3.2.2. Tyrosine Kinase Inhibitors

            5.3.2.3. Others

        5.3.3. Hormonal Drugs

    5.4. Market Attractiveness By Drug Type 

6. Global Anticancer Drugs Market Analysis and Forecasts, By Therapy Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value  Forecast By Therapy Type , 2015-2025

        6.3.1. Chemotherapy

        6.3.2. Targeted Therapy

        6.3.3. Immunotherapy

        6.3.4. Others

    6.4. Market Attractiveness By Therapy Type 

7. Global Anticancer Drugs Market Analysis and Forecasts, By Cancer Type 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast By Cancer Type , 2015-2025

        7.3.1. Lung Cancer

        7.3.2. Breast Cancer

        7.3.3. Leukemia

        7.3.4. Colorectal Cancer

        7.3.5. Others

    7.4. Market Attractiveness By Cancer Type 

8. Global Anticancer Drugs Market Analysis and Forecasts, By Region

    8.1. Key Findings

    8.2. Market Value Forecast By Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific  

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Market Attractiveness By Region

9. North America Anticancer Drugs Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

        9.1.2. Key Trends

    9.2. Market Value Forecast By Drug Type , 2015-2025

        9.2.1. Cytotoxic Drugs

            9.2.1.1. Alkylating Agents

            9.2.1.2. Antimetabolites

            9.2.1.3. Others

        9.2.2. Targeted Drugs

            9.2.2.1. Monoclonal Antibodies

            9.2.2.2. Tyrosine Kinase Inhibitors

            9.2.2.3. Others

        9.2.3. Hormonal Drugs

    9.3. Market Value Forecast By Therapy Type , 2015-2025

        9.3.1. Chemotherapy

        9.3.2. Targeted Therapy

        9.3.3. Immunotherapy

        9.3.4. Others

    9.4. Market Value Forecast By Cancer Type , 2015-2025

        9.4.1. Lung Cancer

        9.4.2. Breast Cancer

        9.4.3. Leukemia

        9.4.4. Colorectal Cancer

        9.4.5. Others

    9.5. Market Value Forecast By Country, 2015-2025

        9.5.1. U.S.

        9.5.2. Canada

    9.6. Market Attractiveness Analysis 

        9.6.1. By Drug Type 

        9.6.2. By Therapy Type 

        9.6.3. By Cancer Type 

        9.6.4. By Country

10. Europe Anticancer Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

        10.1.2. Key Trends

    10.2. Market Value Forecast By Drug Type , 2015-2025

        10.2.1. Cytotoxic Drugs

            10.2.1.1. Alkylating Agents

            10.2.1.2. Antimetabolites

            10.2.1.3. Others

        10.2.2. Targeted Drugs

            10.2.2.1. Monoclonal Antibodies

            10.2.2.2. Tyrosine Kinase Inhibitors

            10.2.2.3. Others

        10.2.3. Hormonal Drugs

    10.3. Market Value Forecast By Therapy Type , 2015-2025

        10.3.1. Chemotherapy

        10.3.2. Targeted Therapy

        10.3.3. Immunotherapy

        10.3.4. Others

    10.4. Market Value Forecast By Cancer Type , 2015-2025

        10.4.1. Lung Cancer

        10.4.2. Breast Cancer

        10.4.3. Leukemia

        10.4.4. Colorectal Cancer

        10.4.5. Others

    10.5. Market  Value  Forecast By Country / Sub-region, 2015-2025

        10.5.1. U.K. 

        10.5.2. Germany

        10.5.3. France

        10.5.4. Italy 

        10.5.5. Spain 

        10.5.6. Rest of Europe

    10.6. Market Attractiveness Analysis 

        10.6.1. By Drug Type 

        10.6.2. By Therapy Type 

        10.6.3. By Cancer Type 

        10.6.4. By Country / Sub-region

11. Asia Pacific Anticancer Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

        11.1.2. Key Trends

    11.2. Market Value Forecast By Drug Type , 2015-2025

        11.2.1. Cytotoxic Drugs

            11.2.1.1. Alkylating Agents

            11.2.1.2. Antimetabolites

            11.2.1.3. Others

        11.2.2. Targeted Drugs

            11.2.2.1. Monoclonal Antibodies

            11.2.2.2. Tyrosine Kinase Inhibitors

            11.2.2.3. Others

        11.2.3. Hormonal Drugs

    11.3. Market Value Forecast By Therapy Type , 2015-2025

        11.3.1. Chemotherapy

        11.3.2. Targeted Therapy

        11.3.3. Immunotherapy

        11.3.4. Others

    11.4. Market Value Forecast By Cancer Type , 2015-2025

        11.4.1. Lung Cancer

        11.4.2. Breast Cancer

        11.4.3. Leukemia

        11.4.4. Colorectal Cancer

        11.4.5. Others

    11.5. Market Value Forecast By Country / Sub-region, 2015-2025

        11.5.1. China

        11.5.2. Japan

        11.5.3. India

        11.5.4. Australia & New Zealand

        11.5.5. Rest of Asia Pacific

    11.6. Market Attractiveness Analysis 

        11.6.1. By Drug Type 

        11.6.2. By Therapy Type 

        11.6.3. By Cancer Type 

        11.6.4. By Country / Sub-region

12. Latin America Anticancer Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

        12.1.2. Key Trends

    12.2. Market Value Forecast By Drug Type , 2015-2025

        12.2.1. Cytotoxic Drugs

            12.2.1.1. Alkylating Agents

            12.2.1.2. Antimetabolites

            12.2.1.3. Others

        12.2.2. Targeted Drugs

            12.2.2.1. Monoclonal Antibodies

            12.2.2.2. Tyrosine Kinase Inhibitors

            12.2.2.3. Others

        12.2.3. Hormonal Drugs

    12.3. Market Value Forecast By Therapy Type , 2015-2025

        12.3.1. Chemotherapy

        12.3.2. Targeted Therapy

        12.3.3. Immunotherapy

        12.3.4. Others

    12.4. Market Value Forecast By Cancer Type , 2015-2025

        12.4.1. Lung Cancer

        12.4.2. Breast Cancer

        12.4.3. Leukemia

        12.4.4. Colorectal Cancer

        12.4.5. Others

    12.5. Market Value Forecast By Country / Sub-region, 2015-2025

        12.5.1. Brazil

        12.5.2. Mexico

        12.5.3. Rest of Latin America

    12.6. Market Attractiveness Analysis 

        12.6.1. By Drug Type 

        12.6.2. By Therapy Type 

        12.6.3. By Cancer Type 

        12.6.4. By Country / Sub-region

13. Middle East & Africa Anticancer Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

        13.1.2. Key Trends

    13.2. Market  Value  Forecast By Drug Type , 2015-2025

        13.2.1. Cytotoxic Drugs

            13.2.1.1. Alkylating Agents

            13.2.1.2. Antimetabolites

            13.2.1.3. Others

        13.2.2. Targeted Drugs

            13.2.2.1. Monoclonal Antibodies

            13.2.2.2. Tyrosine Kinase Inhibitors

            13.2.2.3. Others

        13.2.3. Hormonal Drugs

    13.3. Market  Value  Forecast By Therapy Type , 2015-2025

        13.3.1. Chemotherapy

        13.3.2. Targeted Therapy

        13.3.3. Immunotherapy

        13.3.4. Others

    13.4. Market  Value  Forecast By Cancer Type , 2015-2025

        13.4.1. Lung Cancer

        13.4.2. Breast Cancer

        13.4.3. Leukemia

        13.4.4. Colorectal Cancer

        13.4.5. Others

    13.5. Market Value Forecast By Country / Sub-region, 2015-2025

        13.5.1. GCC Countries

        13.5.2. South Africa

        13.5.3. Rest of MEA

    13.6. Market Attractiveness Analysis 

        13.6.1. By Drug Type 

        13.6.2. By Therapy Type 

        13.6.3. By Cancer Type 

        13.6.4. By Country / Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis By Company (2016)

    14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

        14.3.1. F. Hoffmann-La Roche Ltd

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Product Portfolio

            14.3.1.3. SWOT Analysis

            14.3.1.4. Financial Overview

            14.3.1.5. Strategic Overview

        14.3.2. Eli Lilly and Company

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Product Portfolio

            14.3.2.3. SWOT Analysis

            14.3.2.4. Financial Overview

            14.3.2.5. Strategic Overview

        14.3.3. Novartis AG

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Product Portfolio

            14.3.3.3. SWOT Analysis

            14.3.3.4. Financial Overview

            14.3.3.5. Strategic Overview

        14.3.4. Pfizer Inc

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. SWOT Analysis

            14.3.4.4. Financial Overview

            14.3.4.5. Strategic Overview

        14.3.5. Bayer AG

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Product Portfolio

            14.3.5.3. SWOT Analysis

            14.3.5.4. Financial Overview

            14.3.5.5. Strategic Overview

        14.3.6. AstraZeneca

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Product Portfolio

            14.3.6.3. SWOT Analysis

            14.3.6.4. Financial Overview

            14.3.6.5. Strategic Overview

        14.3.7. Takeda Pharmaceutical Company Limited

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Product Portfolio

            14.3.7.3. SWOT Analysis

            14.3.7.4. Financial Overview

            14.3.7.5. Strategic Overview

        14.3.8. Merck & Co., Inc.

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Product Portfolio

            14.3.8.3. SWOT Analysis

            14.3.8.4. Financial Overview

            14.3.8.5. Strategic Overview

        14.3.9. CELGENE CORPORATION

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Product Portfolio

            14.3.9.3. SWOT Analysis

            14.3.9.4. Financial Overview

            14.3.9.5. Strategic Overview

        14.3.10. Amgen Inc

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Product Portfolio

            14.3.10.3. SWOT Analysis

            14.3.10.4. Financial Overview

            14.3.10.5. Strategic Overview

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Anticancer Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025